Back to top

gene-editing: Archive

Zacks Equity Research

SRPT Provides Pipeline Updates on Rare Muscular Disorder Therapies

Following positive FDA feedback, Sarepta advances a fourth LGMD program to clinical development.

RHHBYPositive Net Change SRPTPositive Net Change ANIPPositive Net Change CTMXPositive Net Change

Zacks Equity Research

VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study

Verve Therapeutics stock rises on demonstrating superior LDL-C lowering ability in a phase Ib study of VERVE-102 in patients with HeFH and/or CAD.

LLYPositive Net Change BAYRYNegative Net Change ADMANegative Net Change VERVPositive Net Change

Sundeep Ganoria

Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.

The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the new HHS Secretary.

MRNAPositive Net Change NVAXPositive Net Change SRPTPositive Net Change CRSPPositive Net Change PCVXPositive Net Change

Ekta Bagri

Promising Genomics & Synthetic Biology Stocks to Consider in 2025

Investors interested in the Genomics and Synthetic Biology theme should consider these stocks: Twist Bioscience Corporation, Wave Life Sciences, and CRISPR Therapeutics AG.

ILMNPositive Net Change BEAMPositive Net Change WVEPositive Net Change NTLAPositive Net Change CRSPPositive Net Change TWSTNegative Net Change

Sundeep Ganoria

How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion

We advise investors with a long-term horizon to remain invested in Sarepta stock, given its encouraging commercial portfolio and robust pipeline potential.

RHHBYPositive Net Change SRPTPositive Net Change PTCTPositive Net Change ARWRPositive Net Change

Zacks Equity Research

Novartis Reports Updated Positive Data From Phase III SMA Program

NVS reports new safety and efficacy data from the phase III program for its investigational OAV101 IT gene therapy for SMA patients.

NVSPositive Net Change RHHBYPositive Net Change DVAXPositive Net Change GILDPositive Net Change

Urmimala Biswas

Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight

Betting on AI-driven precision oncology companies presents a compelling long-term opportunity for investors. Some of the stocks in focus are BTAI, TEM and DGX.

DGXNegative Net Change NVDANegative Net Change BTAINegative Net Change PLTRPositive Net Change TEMNegative Net Change

Zacks Equity Research

SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion

Despite the reported death, Sarepta maintains that its gene therapy has a favorable 'benefit-risk profile.'

RHHBYPositive Net Change SRPTPositive Net Change ANIPPositive Net Change CTMXPositive Net Change

Zacks Equity Research

Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down

EDIT stock is down following the announcement of dismal fourth-quarter 2024 results as both earnings and revenues miss estimates.

BMRNPositive Net Change GILDPositive Net Change VRTXPositive Net Change EDITPositive Net Change